Wealth Enhancement Advisory Services
ORIC icon

Wealth Enhancement Advisory Services’s Oric Pharmaceuticals ORIC Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$258K Buy
21,426
+4,477
+26% +$55.7K ﹤0.01% 3507
2026
Q2 		$184K Buy
16,949
+5,202
+44% +$47.2K ﹤0.01% 3620
2026
Q1 		$104K Buy
+11,747
New +$133K ﹤0.01% 3310
2025
Q4 		– Sell
-10,002
Closed -$141K – 3761
2025
Q3 		$141K Buy
+10,002
New +$105K ﹤0.01% 3256

Other funds holding ORIC

Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Wealth Enhancement Advisory Services's ORIC Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Oric Pharmaceuticals (ORIC) stake by 26% in Q3 2026, buying an estimated $55.7K and bringing the position to 21,426 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #3507.

Wealth Enhancement Advisory Services first reported a position in ORIC in Q3 2025 and has held it in 4 quarters since. 19 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • Wealth Enhancement Advisory Services held 21,426 shares of Oric Pharmaceuticals worth $258K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 4,477 Oric Pharmaceuticals shares in Q3 2026, an estimated $55.7K.
  • Oric Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3507 holding.
  • Wealth Enhancement Advisory Services first reported a position in Oric Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 19 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.